Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2757 - Circulating free tumour-derived DNA (ctDNA) to detect EGFR mutation in patients (pts) with advanced NSCLC (aNSCLC): French subset analysis of the ASSESS study


10 Oct 2016


Poster display


Marc Denis


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


M.G. Denis1, M.P. Lafourcade2, G. Le Garff3, C. Dayen4, L. Falchero5, P. Thomas6, C. Locher7, G. Fraboulet8, G. Oliviero9, M. Licour10, N. Normanno11, M. Reck12, O. Molinier13

Author affiliations

  • 1 Department Of Biochemistry, CHU de Nantes, 44093 - Nantes/FR
  • 2 Department Of Pneumology, CH d'Angoulême, Angouleme/FR
  • 3 Department Of Pneumology, Hopital Yves Le Foll, St. Brieuc/FR
  • 4 Department Of Pneumology, Centre Hospitalier St. Quentin, St Quentin/FR
  • 5 Pneumologie Et Cancérologie Thoracique, CH Villefranche-Sur-Saône, Villefranche-sur-Saône Cedex/FR
  • 6 Department Of Pneumology, CHI Alpes du Sud - Site de Gap, Gap/FR
  • 7 Department Of Pneumology, Centre hospitalier général Meaux, Meaux/FR
  • 8 Department Of Oncology, Hopital René Dubos, Pontoise/FR
  • 9 Department Of Pneumology, CH de Longjumeau, Longjumeau/FR
  • 10 Department Of Epidemiology And Biometry, AstraZeneca, Courbevoie/FR
  • 11 Cell Biology And Biotherapy Unit, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, Napoli/IT
  • 12 Department Of Thoracic Oncology, LungenClinic Grosshansdorf GmbH, Grosshansdorf/DE
  • 13 Centre De Coordination En Cancérologie, Centre Hospitalier Du Mans, Le Mans/FR


Abstract 2757


ASSESS (non-interventional diagnostic study NCT01785888) assessed the concordance of EGFR mutation status in tumour samples and plasma ctDNA in pts with aNSCLC in Europe and Japan. Subset data for pts from France are presented.


Pts: stage IIIA/B/IV chemo-/TKI-naïve NSCLC. Primary endpoint: EGFR mutation status concordance between matched plasma and tumour samples. Tumour testing was performed locally as per local practice; plasma testing was centralised. ctDNA was extracted using the PureLink Virus Kit on an iPrep Purification Instrument (Life Technologies) and EGFR mutations detected via the approved Therascreen EGFR RGQ kit (Qiagen).


Of 1311 enrolled pts, 145 were from France (mean age 64 years, 64% male, 83% ever-smokers). Most samples were collected from primary tumours (81%); collection was mostly via bronchoscopy (38%) and image-guided core biopsy (19%). Of 130 pts with available tissue, 126 were evaluable for EGFR; activating mutations were found in 13 (EGFR mutation frequency 10%). 10 pts tested positive for EGFR mutations in plasma (EGFR mutation frequency 7%). Mutation rate was significantly higher in never- vs ever-smokers (stepwise logistic regression: tumour p 


These real-world data confirm ctDNA as a powerful alternative sample for EGFR mutation analysis in aNSCLC.

Matched tissue/cytology samples (N = 126)

Unadjusted parameters n/N % Exact 95% confidence interval
Concordance 120/126 95.2 89.9, 98.2
Sensitivity 8/13 61.5 31.6, 86.1
Specificity 112/113 99.1 95.2, 100.0
Positive-predictive value 8/9 88.9 51.8, 99.7
Negative-predictive value 112/117 95.7 90.3, 98.6

Clinical trial identification


Legal entity responsible for the study





M.G. Denis: Grants/Research support/consultant: AstraZeneca, Qiagen, Roche Pharma, and Boehringer Ingelheim. G. Le Garff: Clin. Trial: Lilly, Roche, AstraZeneca. All financial contributions except MUTACT study (AZ) paid by clinical research unit. Board: Novartis. Inv. to Congress: AZ (

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings